Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has granted fast track designation to Synageva BioPharma's SBC-102, an enzyme replacement therapy for lysosomal acid lipase (LAL) deficiency.
Subscribe to our email newsletter
SBC-102, which is under clinical trials, is a recombinant human lysosomal acid lipase enzyme responsible for the breakdown of cholesteryl esters and triglycerides.
Synageva R&D CMO and head Anthony Quinn said the fast track program is designed to facilitate drug development and expedite the review of drugs to treat serious diseases like LAL Deficiency.
"We look forward to work closely with the FDA as we complete clinical development to facilitate regulatory review and accelerate the delivery of a treatment for patients suffering from this devastating disease," Quinn said.